Kyntra Bio (KYNB) has received $4 million from AstraZeneca Treasury (AZN), completing the payments for their 2025 share purchase agreement, Kyntra Bio said in a Tuesday filing.
In 2025, Kyntra Bio sold its Chinese operations to AstraZeneca for about approximately $220 million and the $4 million payment is second and final holdback under the deal, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.